ePoster Presentations:
- Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study subgroup analyses
- Presenter:
Mark Roberts , MD, Consultant Neurologist,Salford Royal NHS Foundation Trust , Greater Manchester Neurosciences Centre,United Kingdom (ePoster #196)
- Presenter:
- Living with late-onset Pompe disease in the
UK : interim results characterising the patient journey and burden on physical, emotional and social quality of life- Presenter:
Allan Muir , Chair of theBoard of Trustees , Pompe Support Network,United Kingdom (ePoster #201)
- Presenter:
Cipaglucosidase alfa/miglustat is an investigational therapy that is not yet approved by any regulatory agency.
The posters will be made available on the Amicus website following their respective presentations at the congress.
For more information on the 26th International Annual Congress of the
About Amicus Therapeutics
CONTACT:
Investors:
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Head of
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
Source:
2021 GlobeNewswire, Inc., source